Tempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495

Tempest Therapeutics (TPST) announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S. Food and Drug Administration, FDA, to evaluate TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin, PGE2, signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous Polyposis, FAP.